Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WAT
WAT logo

WAT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Waters Corp (WAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
374.930
1 Day change
-1.05%
52 Week Range
414.150
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Waters Corp (WAT) does not present a strong buying opportunity at this time for a beginner investor with a long-term strategy. While there are some positive indicators, such as Congress trading data showing a significant purchase and analysts raising price targets, the technical indicators, hedge fund selling trends, and lack of strong proprietary trading signals suggest a cautious approach. The stock's current price trend and lack of immediate catalysts do not align with the user's impatience and unwillingness to wait for optimal entry points.

Technical Analysis

The MACD is negative and expanding (-2.796), indicating bearish momentum. RSI is neutral at 39.619, and moving averages are converging, showing no clear direction. The stock is trading below the pivot level (363.395) and closer to the first support level (353.562), suggesting potential downside risk.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The Open Interest Put-Call Ratio of 0.68 and Option Volume Put-Call Ratio of 0.92 indicate a slightly bullish sentiment but not strong enough to suggest a decisive trading opportunity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
8

Positive Catalysts

  • Congress trading data shows a significant purchase in the last 90 days, with a median amount of $3.3M.

  • Analysts have raised price targets recently, with HSBC and Wolfe Research providing optimistic outlooks.

  • The stock is part of the life sciences tools sector, which has potential for recovery according to analysts.

Neutral/Negative Catalysts

  • Hedge funds are selling, with a 125.80% increase in selling activity last quarter.

  • Technical indicators show bearish momentum and no clear upward trend.

  • Lack of recent news or event-driven catalysts to drive immediate price action.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess growth trends or recent performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. Recent ratings include Neutral from Piper Sandler and BofA, while HSBC and Wolfe Research are more optimistic with Buy and Outperform ratings. Price targets range from $345 to $435, with a general upward adjustment reflecting improved sentiment in the life sciences tools sector.

Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
Wall Street analysts forecast WAT stock price to rise
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 378.890
sliders
Low
350
Averages
414.08
High
480
Current: 378.890
sliders
Low
350
Averages
414.08
High
480
Evercore ISI
NULL
to
Outperform
maintain
$380 -> $410
AI Analysis
2026-07-06
New
Reason
Evercore ISI
Price Target
$380 -> $410
AI Analysis
2026-07-06
New
maintain
NULL
to
Outperform
Reason
Evercore ISI raised the firm's price target on Waters to $410 from $380 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.
Bernstein
Eve Burstein
resume
$435
2026-06-26
Reason
Bernstein
Eve Burstein
Price Target
$435
2026-06-26
resume
Reason
Bernstein analyst Eve Burstein resumed coverage of Waters with an Outperform rating and $435 price target following a return from maternity leave. \"Many things\" are going right for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm says new drug approvals, trial starts, and funding are all better in the last 12 months versus the 12 months prior. Bernstein believes funding will start translating into customer spend while re-shoring will drive incremental investment at a time when AI-driven demand for semiconductor-related tools will continue to grow.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WAT
Unlock Now

People Also Watch